Loperamide
- Generic Name
- Loperamide
- Brand Names
- Diamode, Imodium, Imodium Multi-symptom Relief
- Drug Type
- Small Molecule
- Chemical Formula
- C29H33ClN2O2
- CAS Number
- 53179-11-6
- Unique Ingredient Identifier
- 6X9OC3H4II
- Background
Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as diphenoxylate and haloperidol. Due to pharmacologic...
- Indication
Loperamide is indicated for the relief of diarrhea, including Travelers’ Diarrhea. As an off-label use, it is often used to manage chemotherapy-related diarrhea.
- Associated Conditions
- Diarrhea, Traveler's Diarrhea
- Associated Therapies
- -
A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- McNeil AB
- Target Recruit Count
- 48
- Registration Number
- NCT04186936
- Locations
- 🇷🇺
"Scientific and Research centre Eco-safety" Limited Liability Company, Saint-Petersburg, Russian Federation
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 1
- Registration Number
- NCT04172597
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04038619
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Gut Transit Effect on Enterohepatic Circulation
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- University Hospital Plymouth NHS Trust
- Target Recruit Count
- 19
- Registration Number
- NCT03501498
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, United Kingdom
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
- Conditions
- Interventions
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 11
- Registration Number
- NCT03094052
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Tibial Nerve Stimulation in Combination With Biofeedback
- Conditions
- Interventions
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2016-09-05
- Lead Sponsor
- University Hospital, Linkoeping
- Registration Number
- NCT02888899
- Locations
- 🇸🇪
Pelvic floor unit, University Hospital in Linköping, Linköping, Sweden
Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT02711891
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Queen Elizabeth II Health Sciences Centre
- Target Recruit Count
- 50
- Registration Number
- NCT02686645
A Study of Abemaciclib in Healthy Participants
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT02677844
- Locations
- 🇺🇸
Covance Clinical Research Unit, Evansville, Indiana, United States
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 224
- Registration Number
- NCT02441946
- Locations
- 🇺🇸
Millennium Oncology, Houston, Texas, United States
🇨🇳For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Taipei, Taiwan
🇺🇸Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.